These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31197750)

  • 21. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
    Kerkmeijer LSM; Renkens MPL; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Garcia-Garcia HM; Kraak R; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2022 Mar; 17(16):1340-1347. PubMed ID: 34483094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials.
    Campos CM; Caixeta A; Franken M; Bartorelli AL; Whitbourn RJ; Wu CJ; Li Paul Kao H; Rosli MA; Carrie D; De Bruyne B; Stone GW; Serruys PW; Abizaid A;
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):387-395. PubMed ID: 28471086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials.
    Kang SH; Gogas BD; Jeon KH; Park JS; Lee W; Yoon CH; Suh JW; Hwang SS; Youn TJ; Chae IH; Kim HS
    EuroIntervention; 2018 Mar; 13(16):1904-1913. PubMed ID: 29278353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
    Stone GW; Gao R; Kimura T; Kereiakes DJ; Ellis SG; Onuma Y; Cheong WF; Jones-McMeans J; Su X; Zhang Z; Serruys PW
    Lancet; 2016 Mar; 387(10025):1277-89. PubMed ID: 26825231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
    Stone GW; Ellis SG; Gori T; Metzger DC; Stein B; Erickson M; Torzewski J; Williams J; Lawson W; Broderick TM; Kabour A; Piegari G; Cavendish J; Bertolet B; Choi JW; Marx SO; Généreux P; Kereiakes DJ;
    Lancet; 2018 Oct; 392(10157):1530-1540. PubMed ID: 30266412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-year clinical outcomes using the bioresorbable vascular scaffold: Insights from the FRANCE ABSORB registry.
    Landolff Q; Lefèvre T; Fajadet J; Sainsous J; Lhermusier T; Elhadad S; Tarragano F; Ranc S; Ghostine S; Cayla G; Marco F; Garot P; Maillard L; Motreff P; Delarche N; De Labriolle A; Pansieri M; Morelle JF; Cazaux P; Moulichon ME; Chopat P; Angoulvant D; Bataille V; Le Breton H; Koning R;
    Arch Cardiovasc Dis; 2022 Oct; 115(10):505-513. PubMed ID: 36123284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
    Kimura T; Kozuma K; Tanabe K; Nakamura S; Yamane M; Muramatsu T; Saito S; Yajima J; Hagiwara N; Mitsudo K; Popma JJ; Serruys PW; Onuma Y; Ying S; Cao S; Staehr P; Cheong WF; Kusano H; Stone GW;
    Eur Heart J; 2015 Dec; 36(47):3332-42. PubMed ID: 26330419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scaffold underexpansion and late lumen loss after bioresorbable scaffold implantation: Insights from ABSORB JAPAN trial.
    Okada K; Honda Y; Kitahara H; Ikutomi M; Kameda R; Brooke Hollak M; Yock PG; Popma JJ; Kusano H; Cheong WF; Sudhir K; Fitzgerald PJ; Kimura T;
    Int J Cardiol Heart Vasc; 2020 Dec; 31():100623. PubMed ID: 32944608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef HM; Wiebe J; Kastner J; Mehilli J; Muenzel T; Naber C; Neumann T; Richardt G; Schmermund A; Woehrle J; Zahn R; Riemer T; Achenbach S; Hamm CW
    EuroIntervention; 2017 Dec; 13(11):1311-1318. PubMed ID: 28829745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
    Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice - results from the European Absorb Consortium.
    Wiebe J; Hofmann FJ; West N; Baumbach A; Carrie D; Bermudez EP; Cayla G; Hernandez FH; de la Torre Hernandez JM; Koning R; Loi B; Moscarella E; Tarantini G; Zaman A; Lober C; Riemer T; Achenbach S; Hamm CW; Nef HM;
    Catheter Cardiovasc Interv; 2022 Feb; 99(3):533-540. PubMed ID: 34463427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.
    Stone GW; Kimura T; Gao R; Kereiakes DJ; Ellis SG; Onuma Y; Chevalier B; Simonton C; Dressler O; Crowley A; Ali ZA; Serruys PW
    JAMA Cardiol; 2019 Dec; 4(12):1261-1269. PubMed ID: 31561250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials.
    Collet C; Asano T; Miyazaki Y; Tenekecioglu E; Katagiri Y; Sotomi Y; Cavalcante R; de Winter RJ; Kimura T; Gao R; Puricel S; Cook S; Capodanno D; Onuma Y; Serruys PW
    Eur Heart J; 2017 Sep; 38(33):2559-2566. PubMed ID: 28430908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.